POZN - Pozen Inc - Page 11

niceeeeeeeeeeeeeeeeeeeeeeeee pop 2day,,,,,,,,,,,, close at hod?????

called this yesterday and just watched it take off. i hate myself a little bit more each day.

don't look now

This thing looks strong...

next couple of weeks should be interesting

With an FDA date set for 4/30, and like 1.6 million shorts who are running out of time to cover...

Pozen Inc. $ 10.98
POZN 0.37

Short Interest (Shares Short) 1,582,300
Days To Cover (Short Interest Ratio) 13.3
Short Percent of Float 5.79 %
Short Interest - Prior 1,675,700
Short % Increase / Decrease -5.57 %
Short Squeeze Ranking™ 48

% From 52-Wk High ($ 9.89 ) 9.93 %
% From 52-Wk Low ($ 5.16 ) 53.01 %
% From 200-Day MA ($ 6.81 ) 37.98 %
% From 50-Day MA ($ 6.66 ) 39.34 %
Price % Change (52-Week) 61.90 %

Shares Float 27,321,651
Total Shares Outstanding 29,834,808
% Owned by Insiders 8.40 %
% Owned by Institutions 46.30 %
Market Cap. $ 327,586,192
Trading Volume - Today 1,259,440
Trading Volume - Average 118,600
Trading Volume - Today vs. Average 1061.92 %
Earnings Per Share -0.23
PE Ratio
Record Date 2010-MarB

Sector Healthcare
Industry Drug Manufacturers - Other
Exchange NAS
Data Provided Without Warranty

http://finance.yahoo.com/news/Pozen-....html?x=0&.v=1



strange that we'd drop 5% after such a positive mention.

that guy is a douche fraud who impersonated a doctor and has been bashing the crap outta dndn since its 2 dollar days. I don't take him too seriously

anyone still in this? i was hoping for a run into low teens but looks like she will be hanging around here until fda news.

FDA date 4/30/10, so things should pick up for this one. They also have earnings coming out 4/29/10. Not sure why they set it up like that?

sounds fishy.

They beat expectations!!!

POZEN Reports First Quarter 2010 Results
POZEN Inc. (NASDAQ: POZN), today announced results for the first quarter ended March 31, 2010.

First Quarter Results

POZEN reported a net loss of $(3.0) million, or $(0.10) per share on a diluted basis, for the first quarter of 2010, compared to a net loss of $(3.5) million, or $(0.12) per share on a diluted basis, for the first quarter of 2009.

For the first quarter of 2010, POZEN reported revenue of $6.9 million resulting from royalty on sales of Treximet® (sumatriptan / naproxen sodium) of $3.8 million and the amortization of upfront payments received pursuant to the collaboration agreement with AstraZeneca of $3.1 million. Revenue for the first quarter ended March 31, 2009 totaled $8.8 million, resulting from royalty on sales of Treximet of $1.0 million, $4.7 million of revenue for development work performed under our collaboration agreement and the amortization of upfront payments of $3.1 million.

Operating expenses for the first quarter of 2010 totaled $9.9 million as compared to $12.5 million for the comparable period in 2009. The decrease in operating expenses was primarily due to a decrease in costs associated with the development program for VIMOVO™ (naproxen / esomeprazole magnesium), partially offset by increases in the PA32540 development program and patent litigation expenses.

At March 31, 2010, cash, cash equivalents and short-term investments totaled $36.7 million compared to $46.7 million at December 31, 2009. The Company has an accounts receivable balance of $3.8 million from GlaxoSmithKline at March 31, 2010.

nice jump there.. shorts covering?

fda decision tomorrow. price shot up 10% and another 3% afterhours today.

good luck to all in this. I was gonna take half off the table but decided to risk it. might still take profits tom depending on action...

FDA Decision Today. Up 2.2% right now.

should get aprooved IMO! History in making here with Pozen Inc.

I think it will be approved as well. But the real history was made when DNDN's drug got approved yesterday!